GlassScriptPhysician profile
Dwana R Shabazz
NPI 1548296817
$6,536.53
in general payments reported to CMS, 2019-2025
47 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $484 · 2021: $893 · 2022: $1,122 · 2023: $908 · 2024: $1,540 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Consulting Fee: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.88 |
| Consulting Fee | $1,012.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,316.28 | 2019-2025 | |
| Janssen Biotech, INC. | $656.38 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $506.28 | 2019-2025 | |
| Smith+Nephew, INC. | $469.05 | 2019-2025 | Collagenase Santyl, Regranex, Grafix Pl |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $432.89 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Galderma Laboratories, L.P. | $346.19 | 2019-2024 | Twyneo, Oracea, Aklief |
| Sun Pharmaceutical Industries INC. | $295.69 | 2020-2025 | Absorica Ld, Winlevi |
| Paratek Pharmaceuticals, INC. | $230.13 | 2021-2025 | Nuzyra |
| Lilly USA, LLC | $207.90 | 2020-2024 | Taltz, Olumiant, Zepbound |
| Organogenesis INC. | $188.96 | 2020-2023 | Puraply |
| Mayne Pharma Commercial LLC | $188.72 | 2019-2022 | |
| Sandoz INC. | $145.37 | 2019-2020 | |
| Integra Lifesciences Corporation | $126.62 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Incyte Corporation | $125.84 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $107.66 | 2019-2024 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $101.96 | 2019-2022 | |
| Leo Pharma INC. | $88.45 | 2019-2025 | Anzupgo |
| Ucb, INC. | $82.77 | 2019-2022 | |
| Kerecis Limited | $75.19 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Stryker Corporation | $64.73 | 2022-2023 | Omega, Iconix, Regenkit-Tht |
| Heron Therapeutics, INC. | $62.82 | 2021-2023 | Zynrelef |
| Triad Life Sciences INC. | $57.41 | 2022 | |
| Averitas Pharma INC. | $54.92 | 2025 | Qutenza |
| Nabriva Therapeutics, Plc | $51.30 | 2022 | |
| Strata Skin Sciences, INC. | $48.24 | 2022 | |
| Vyne Pharmaceuticals INC. | $46.50 | 2020 | |
| Bioventus LLC | $42.04 | 2022 | |
| Convatec INC. | $41.70 | 2023 | |
| Genzyme Corporation | $40.73 | 2019 | |
| Medtronic, INC. | $29.23 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Amgen INC. | $26.08 | 2024 | Krystexxa |
| Merck Sharp & Dohme LLC | $25.55 | 2019 | |
| Ibsa Pharma INC. | $23.26 | 2022 | |
| Biotissue Holdings INC. | $22.92 | 2021 | |
| Abbott Laboratories | $20.52 | 2021 | |
| Nevro Corp. | $20.23 | 2023 | Senza |
| Glenmark Therapeutics INC. | $20.00 | 2019 | |
| Orthofix Medical, INC. | $19.21 | 2025 | Physio-Stim |
| Dermira, INC. | $17.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.39 | 2023 | Seglentis |
| Solventum Corporation | $16.94 | 2024 | Activ.A.C. |
| Journey Medical Corporation | $15.01 | 2020 | |
| Arcutis Biotherapeutics, INC. | $13.10 | 2024 | Zoryve |
| Apria Healthcare LLC | $12.56 | 2021 | |
| Tactile Systems Technology INC | $12.01 | 2019 | |
| Epi Health, LLC | $11.27 | 2020 | |
| Depuy Synthes Sales INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwana Shabazz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.